[go: up one dir, main page]

MX2018004445A - Particulas coloidales para su uso en medicina. - Google Patents

Particulas coloidales para su uso en medicina.

Info

Publication number
MX2018004445A
MX2018004445A MX2018004445A MX2018004445A MX2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A
Authority
MX
Mexico
Prior art keywords
medicine
colloidal particles
composition
contain
active agent
Prior art date
Application number
MX2018004445A
Other languages
English (en)
Other versions
MX391574B (es
Inventor
Mayo John
Henry William
Wolf-Garraway Richard
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2018004445A publication Critical patent/MX2018004445A/es
Publication of MX391574B publication Critical patent/MX391574B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona una composición que comprende una partícula coloidal que comprende aproximadamente del 0.5 al 20 por ciento en moles de un lípido anfipático derivatizado con un polímero hidrófilo biocompatible para su uso en medicina, en la que dicha composición no contiene ningún agente farmacéuticamente activo.
MX2018004445A 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina. MX391574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (2)

Publication Number Publication Date
MX2018004445A true MX2018004445A (es) 2018-08-14
MX391574B MX391574B (es) 2025-03-21

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004445A MX391574B (es) 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina.

Country Status (15)

Country Link
US (3) US20190192664A1 (es)
EP (1) EP3362039A1 (es)
JP (1) JP7160678B2 (es)
KR (1) KR20180067616A (es)
CN (1) CN108472246A (es)
AU (1) AU2016336929B2 (es)
BR (1) BR112018007399A2 (es)
CA (1) CA3036111C (es)
EA (1) EA201890703A1 (es)
GB (1) GB201518172D0 (es)
HK (1) HK1256814A1 (es)
IL (1) IL258567B2 (es)
MX (1) MX391574B (es)
SG (2) SG10202010711UA (es)
WO (1) WO2017064276A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4055032A1 (en) * 2019-11-07 2022-09-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
PT1079805E (pt) 1998-04-27 2005-03-31 Opperbas Holding Bv Composicao farmaceutica compreendendo factor viii e lipossomas neutros
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
KR20070086708A (ko) 1999-07-14 2007-08-27 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
DK1633440T3 (da) * 2003-04-15 2008-09-08 Opperbas Holding Bv Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler
AU2006263566A1 (en) * 2005-06-29 2007-01-04 The Research Foundation Of State Of University Of New York At Buffalo Compositions and methods for less immunogenic protein-lip1d complexes
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
DE112010003355T5 (de) 2009-08-21 2012-07-12 Targeted Delivery Technologies Ltd. Veskuläre Formulierungen
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
AU2014224205C1 (en) * 2013-03-08 2019-04-04 Novartis Ag Lipids and lipid compositions for the delivery of active agents

Also Published As

Publication number Publication date
HK1256814A1 (zh) 2019-10-04
SG10202010711UA (en) 2020-12-30
EA201890703A1 (ru) 2018-11-30
CA3036111A1 (en) 2017-04-20
US20190192664A1 (en) 2019-06-27
AU2016336929A1 (en) 2018-05-10
EP3362039A1 (en) 2018-08-22
JP7160678B2 (ja) 2022-10-25
US20210093721A1 (en) 2021-04-01
MX391574B (es) 2025-03-21
JP2018535952A (ja) 2018-12-06
BR112018007399A2 (pt) 2018-10-16
CA3036111C (en) 2023-06-06
AU2016336929B2 (en) 2022-09-29
IL258567A (en) 2018-05-31
IL258567B1 (en) 2025-04-01
GB201518172D0 (en) 2015-11-25
SG11201802956RA (en) 2018-05-30
US20250170244A1 (en) 2025-05-29
KR20180067616A (ko) 2018-06-20
WO2017064276A1 (en) 2017-04-20
IL258567B2 (en) 2025-08-01
CN108472246A (zh) 2018-08-31

Similar Documents

Publication Publication Date Title
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
CA2956871C (en) Compounds active towards bromodomains
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
EP4491184A3 (en) Channel modulators
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
HK1216083A1 (zh) 经动脉的药物递送
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
ZA202503388B (en) Semaglutide in medical therapy
MX2019010852A (es) Nanoparticulas a base de lipidos con estabilidad mejorada.
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
MX2018004445A (es) Particulas coloidales para su uso en medicina.
SMT202200275T1 (it) Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione
GB2528421A (en) Methods and processes for application of drug delivery polymeric coatings
WO2016001905A3 (en) Stable liquid ready-to-use injectable formulation of bortezomib
CA3010981A1 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2017079403A3 (en) Polymeric nanoparticles
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
IL270159B (en) Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases
CA3011003A1 (en) Bacterial ghosts for the treatment of cancer